Experimental analysis reveals SETD2 functions as a tumor suppressor in KRASG12C lung cancer, indicating the role of histone acetylation in its regulation.
Key Points
SETD2 functions as a potent tumor suppressor, and loss of SETD2 accelerates tumor burdens in lung cancer models.
Biochemical analyses indicate that polyacetylation promotes H3K36 methylation by SETD2, enhancing its enzymatic activity.
SETD2 is the key enzyme for H3K36me3 modification, implicating it in epigenetic regulation across various cancer types.
Monoacetylation showcases position-specific effects on SETD2 activity, revealing deeper epigenetic crosstalk in cancer progression.